New Guidelines for Treating Restless Legs Syndrome

Overview of Restless Legs Syndrome

A recent report from the American Academy of Neurology aims to establish guidelines for the treatment of Restless Legs Syndrome (RLS) in adults. These guidelines encompass both pharmacologic and non-pharmacologic strategies tailored to the severity of symptoms. RLS is a movement disorder marked by unpleasant sensations in the limbs, prompting an irresistible urge to move the legs or arms. This condition can severely disrupt sleep quality, leading to additional complications such as mood disorders, reduced quality of life, and decreased productivity.

Research and Evidence

The report, published in The Official Journal of the American Academy of Neurology in 2017, reviewed existing literature using the 2004 American Academy of Neurology evidence rating scheme. The aim was to evaluate the effectiveness of various treatment options, including pharmaceuticals, vitamin supplements, and vibrating pads, in alleviating RLS symptoms. A treatment was deemed clinically significant if it resulted in a minimum change of 3 points on the International Restless Legs Syndrome Study Group rating scale (IRLS). Most studies included in this analysis were short-term, lasting 12 weeks or less, which limits understanding of the long-term risks and side effects associated with these treatments.

Pharmacologic Recommendations

The report encourages clinicians to consider pharmacologic treatments for patients with moderate to severe primary RLS. The most effective medications identified include pramipexole, rotigotine, cabergoline, and gabapentin enacarbil. However, due to the lack of direct comparisons among these medications, there is limited data to suggest any one agent is preferable to another. For clinicians aiming to improve sleep quality or quantity in patients with RLS, selecting a pharmacologic agent known to enhance sleep parameters is advisable.

Non-Pharmacologic Approaches

The report also addresses the various clinical complications associated with RLS, such as anxiety, depression, and iron deficiencies. For patients with identified deficiencies, it is recommended that clinicians prescribe vitamin C and/or vitamin E supplements. Exercise has shown potential as an effective treatment, while other non-pharmacological methods, like vibrating pads, have demonstrated lower effectiveness in alleviating symptoms.

Future Research Directions

Further research is essential to refine the guidelines for long-term treatment of Restless Legs Syndrome (RLS). Conducting direct comparisons of both pharmacologic and non-pharmacologic therapies will enable researchers to develop a comprehensive set of recommendations aimed at effective treatment and symptom management.

Conclusion

The ongoing development of treatment guidelines for Restless Legs Syndrome reflects a commitment to improving patient care and outcomes. As more evidence becomes available, it will enhance the ability of clinicians to provide safe and effective therapies for those affected by this condition.

Written By: Jennifer Newton